Harmony Biosciences Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $959.9M+34.3% YoYTTM through 30 Jun 2026
Net Income $181.3M+24.6% YoYTTM through 30 Jun 2026
Free Cash Flow $354.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 77.2% |
| EBITDA Margin | 26.5% |
| Operating Margin | 24.0% |
| Net Margin | 18.9% |
Returns
18.2%ROE
12.5%ROA
30.0%ROIC
Balance Sheet Health
Debt / Equity0.19x
Current Ratio3.60x
Net Debt-$611.7Mnet cash position
Cash & Equivalents$549.8M
Quality Metrics
Altman Z-Score5.92
Piotroski F-Score6 / 9
FCF Margin37.0%
Rule of 4044.7
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $868.5M
Diluted EPS$3.09TTMFY2025: $2.71
Dividend
No dividend
Capital Allocation
R&D Spend$220.9M
Capex Intensity0.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| WAKIX (pitolisant) Net Product Revenue | $868.5M | +21.5% | View detailsReaffirmed WAKIX net product revenue guidance of $1.0 billion to $1.04 billion for the full year 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.